TH027 for relapsed or refractory solid tumors
Part of Cancer clinical trials.
This trial tests an experimental drug, TH027, in patients with certain solid tumors that have come back or not responded to standard treatments. It aims to see if TH027 is safe and effective, and it's for people with osteosarcoma, neuroblastoma, stomach cancer, or lung cancer that shows a specific marker (CD276) on at least 30% of tumor cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have osteosarcoma, neuroblastoma, stomach cancer, or lung cancer that hasn't responded to standard treatments.
- Your tumor cells have a specific marker called CD276 on at least 30% of them (your doctor can test for this).
- You have at least one tumor that can be measured on a scan (at least about 1 cm in size).
- Your blood counts, heart, liver, and kidney function are within certain safe limits.
- You haven't had CAR-T therapy or other gene-modified cell therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug called JSKN027 for people with advanced solid tumors (cancers that have spread) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
This trial tests a new drug, MB0151, for adults with advanced solid tumors that have somatostatin receptors and have not responded to standard treatments. It aims to see if MB0151 is safe and can shrink tumors.
This trial tests a new drug called BT02 for people with advanced solid tumors who have not had any cancer treatment before. It aims to see if BT02 is safe and how well it works.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.